FDA Approves New Psoriasis Drug

U.S. Food & Drug Administration press release ------ The U.S. Food and Drug Administration yesterday approved Siliq (broadalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection. Siliq is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected) or phototherapy (ultraviolet light treatment) and have failed to respond, or have stopped responding to other systemic therapies. "Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and the approval provides patients with another treatment option for their psoriasis," said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research. "Patients and their health care providers should discuss the benefits and risks of Siliq before considering treatment." To learn more about the FDA approving new psoriasis drug click on the picture below to read the FDA release.

"